Scalable xeno-free manufacturing of extracellular vesicles derived from human mesenchymal stem cells

      Having been investigated in >800 clinical trials without significant adverse events, human mesenchymal stem cells (hMSCs) are a safe and clinically relevant cell source for producing extracellular vesicles (EVs) such as exosomes. Not only can hMSC-EVs deliver exogenous agents including RNA and proteins, hMSC-EVs also inherit the therapeutic potential of hMSCs and have been applied in >20 disease models. However, based on the current state of the art, a single hMSC-EV dose would require an equivalent of >10 hMSC doses to generate, rendering this technology cost-prohibitive.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect